Can a Supplement “Rebuild Cartilage”? What That Claim Would Actually Require

“Rebuilds cartilage” is one of the most common phrases in joint-supplement marketing, and also one of the most biologically demanding claims a product could possibly make — because cartilage is specifically, structurally bad at repairing itself, for reasons that have nothing to do with what nutrients are circulating in the bloodstream. This article explains what that claim would actually require physiologically, why no oral supplement has demonstrated it in humans, and walks through a real, well-documented FTC case where a company made exactly this claim and was found to have no adequate evidence for it — a concrete illustration of why this specific phrase deserves more skepticism than almost any other in this category.

The short version

• Articular cartilage — the smooth tissue cushioning joints — has an unusually poor built-in capacity to repair itself, for structural reasons, not a nutrient deficiency. It’s avascular (no blood supply of its own), has low cell density, and its single cell type (chondrocytes) doesn’t migrate to injury sites the way cells in most other tissues do. When cartilage is damaged, the body doesn’t rebuild it as cartilage — it typically fills the defect with a different, mechanically inferior fibrous tissue, if it fills it at all.
• This is precisely why a joint injury or osteoarthritis, once cartilage loss occurs, doesn’t reliably heal the way a cut or a broken bone does. No circulating nutrient — dietary or supplemental — changes this basic structural limitation, because the problem isn’t lack of raw material; it’s lack of blood supply and cellular access to the damaged area.
• The strongest available human trial data on this specific question — whether glucosamine and/or chondroitin measurably rebuild cartilage — found no evidence that they do. Radiographic analysis (joint space width, a standard measure of cartilage volume) from the large NIH-funded GAIT trial (covered in depth in our companion glucosamine/chondroitin article) found no structural benefit from either ingredient, alone or combined, over 24 weeks or in 2-year follow-up data.
• A real, concrete example of what happens when a company makes this exact claim without adequate evidence: in 2016, the FTC settled charges against Supple LLC, marketer of a glucosamine/chondroitin liquid supplement, over claims that the product “repairs cartilage” and “rebuilds joints and entire joint structures,” among other unsubstantiated claims. The company had taken in more than $150.6 million in sales from 2011 to 2015; the settlement included a $150 million judgment (mostly suspended based on the defendants’ financial condition) and a requirement that any future health claims be backed by real scientific evidence.
• What would genuinely rebuilding cartilage actually require? In current medicine, restoring damaged cartilage requires direct surgical or cell-based intervention — procedures like microfracture surgery (creating tiny fractures in underlying bone to stimulate a repair response), autologous chondrocyte implantation (harvesting a patient’s own cartilage cells, growing them in a lab, and surgically implanting them), or osteochondral grafting (transplanting cartilage-and-bone plugs from elsewhere in the joint or from a donor) — invasive, clinically supervised procedures, not something achievable by taking a capsule.

Why cartilage can’t just “heal itself” the way other tissues do

Most tissue injuries in the body heal through a well-understood process: blood vessels deliver immune cells, growth factors, and progenitor cells to the injury site, inflammation clears damaged material, and new tissue forms to replace what was lost. This is roughly how a cut, a broken bone, or even damaged muscle typically repairs.

Articular cartilage does not have access to this process, for a specific, well-documented structural reason: it’s avascular — it has no blood supply of its own. Chondrocytes (cartilage’s only cell type) rely entirely on nutrients diffusing in from the surrounding joint fluid and underlying bone, a much slower and more limited supply route than a direct blood vessel network. Cartilage also has notably low cell density compared to most tissues, and — this is the detail that matters most for the “rebuild” claim specifically — when cartilage is damaged in a way that doesn’t reach the underlying bone, the body’s usual repair machinery genuinely cannot reach it: blood-borne progenitor cells that would normally migrate to an injury site and differentiate into new tissue simply have no route into the damaged area, and the resident chondrocytes at the defect site do not migrate toward the injury or produce new repair matrix on their own the way cells in most other tissues do.

The practical result: once cartilage is significantly damaged — whether from an acute injury or the gradual degeneration of osteoarthritis — it typically does not heal back as cartilage. If any repair tissue forms at all, it’s often a mechanically inferior fibrous tissue (essentially scar tissue), not the smooth, load-bearing cartilage that was there originally. This is a structural, plumbing-level limitation, not a deficiency of any specific nutrient, vitamin, or supplement ingredient — which is precisely why no amount of dietary glucosamine, chondroitin, collagen, or any other circulating compound can be expected to solve a problem that exists because the repair machinery can’t physically reach the site in the first place.

What the actual trial data shows: no measured structural benefit

This isn’t just a theoretical argument — it’s been directly tested. The GAIT trial (the largest, most rigorous U.S. trial of glucosamine and chondroitin, covered in full in our companion article on that ingredient pair) included radiographic analysis of joint space width — a standard X-ray-based measure of how much cartilage volume remains in a joint — as part of its evaluation. Neither glucosamine nor chondroitin, alone or in combination, showed a measurable structural benefit on this measure, either in the trial’s initial phase or in 2-year follow-up data. This is a direct, specific test of the “does this supplement rebuild cartilage” question, using an objective, non-subjective structural measurement (rather than a self-reported pain score, which is more susceptible to placebo effects) — and it found no evidence supporting the claim.

A real example of this exact claim being made, and challenged

In October 2016, the Federal Trade Commission settled charges against Supple LLC, a Wisconsin-based company that marketed a glucosamine and chondroitin liquid supplement called Supple through infomercials, social media, radio ads, and in-person community events. According to the FTC’s complaint, the company’s marketing — including infomercials structured like a medical talk show — described Supple as providing “complete and long-lasting relief from joint pain,” treating or relieving pain from “all forms of arthritis and fibromyalgia,” providing relief “comparable to drugs or surgery,” and specifically claiming the product “repairs cartilage” and “rebuilds joints and entire joint structures.” The FTC’s complaint stated these claims were false or not adequately substantiated, and separately alleged that one of the product’s on-air “expert” endorsers had an undisclosed close personal and financial relationship with the company (she was married to its creator).

This is not a small or fringe case: the company had taken in more than $150.6 million in sales from 2011 to 2015 alone. The settlement required a $150 million judgment (with most of it suspended based on the defendants’ documented financial condition, a common practice in FTC settlements against defendants who can’t pay the full amount), and a permanent requirement that any future health or pain-relief claims be backed by real scientific evidence, alongside a prohibition on misrepresenting endorsers as independent when they have a financial stake in the product.

This case is now roughly a decade old, but it remains one of the most direct, well-documented, and highest-dollar illustrations available of exactly the claim this article is about being made at scale, challenged, and found unsubstantiated by federal regulators — not a hypothetical concern, a real, adjudicated one.

What actual cartilage repair looks like in medicine today

It’s worth being concrete about what genuinely restoring damaged cartilage currently requires, since it clarifies just how large a claim “rebuilds cartilage” really is. Current medical approaches to cartilage repair are surgical or cell-based, not nutritional:

• Microfracture surgery, where a surgeon creates small fractures in the bone beneath damaged cartilage, deliberately triggering bleeding and a healing response that can partially fill the defect (usually with fibrocartilage, the mechanically inferior repair tissue mentioned above, not true hyaline cartilage).
• Autologous chondrocyte implantation (ACI), where a small sample of a patient’s own healthy cartilage cells is harvested, grown and expanded in a laboratory over several weeks, and then surgically implanted into the damaged area.
• Osteochondral autograft or allograft transplantation, where a plug of healthy cartilage and underlying bone is transplanted from elsewhere in the patient’s own joint (autograft) or from a donor (allograft) into the damaged area.
• Cell-based and tissue-engineering approaches (including stem-cell-derived cartilage research) remain an active area of research, with some promising early results, but are not yet standard, widely available clinical treatments.

Every one of these requires direct surgical access to the joint and specialized clinical expertise — they are fundamentally different in kind, not just degree, from taking an oral supplement. This is the honest scale of what “rebuilding cartilage” actually means in current medicine, and it’s the standard any product claim using that phrase should be measured against.

What we could not check

• We did not conduct a comprehensive review of every supplement marketing case the FTC has pursued over “rebuild cartilage” or similar language — the Supple case is presented as one clear, well-documented, high-dollar illustration, not an exhaustive survey; more recent cases may exist that we did not systematically search for.
• We did not independently review the current state of stem-cell or tissue-engineering research for cartilage regeneration in depth — mentioned briefly as context for what “actual” cartilage repair research looks like, not evaluated as a settled treatment option.
• We did not independently pull the GAIT trial’s radiographic/joint-space-width data tables directly — this finding is drawn from secondary summaries of the trial, consistent with our companion glucosamine/chondroitin article’s sourcing.
• This article does not evaluate every ingredient marketed with cartilage-related claims (e.g., type II collagen, MSM) individually — it addresses the physiological plausibility of the claim itself, which applies regardless of which specific ingredient is marketed alongside it.

Our rating, and why

Not applicable. This article evaluates a claim pattern and the underlying biology behind it, not a specific ingredient, so this site’s evidence-classification scale doesn’t apply in the usual sense. Its purpose is to give readers a concrete, physiologically grounded reason to be skeptical of “rebuilds cartilage” language specifically — a claim that, per the structural realities of cartilage biology and the one detailed real-world enforcement case covered here, does not currently have credible support behind it for any oral supplement.

Sources

1. Federal Trade Commission. Marketers of Joint Pain Supplement Agree to Settle FTC Charges of Deceptive Advertising, Endorsements. Press release, October 5, 2016. https://www.ftc.gov/news-events/news/press-releases/2016/10/marketers-joint-pain-supplement-agree-settle-ftc-charges-deceptive-advertising-endorsements (read in full)
2. Strategies for Articular Cartilage Repair and Regeneration. Frontiers in Bioengineering and Biotechnology. (read via abstract and secondary summaries)
3. Major biological obstacles for persistent cell-based regeneration of articular cartilage. (read via abstract and secondary summaries)
4. Clegg DO, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis (GAIT trial), and its 2-year radiographic follow-up analysis — see full citations in our companion glucosamine and chondroitin article.